For Q3 2026, Ultragenyx is expected to report a net loss of $1.15 per share on revenue of $155.6 million, with its current $52.45 share price trading well below the $84.30 consensus analyst price target. Investors are primarily focused on the commercial performance of Crysvita and Dojolvi, which represent the company's primary revenue streams.
Recent market sentiment has been supported by advancements in the gene therapy pipeline, specifically the UX701 program for Wilson disease and the DTX401 program for GSDIa. Analysts will be looking for confirmation of regulatory filing timelines and narrowing operational losses as the company targets long-term profitability.